BALCHEM CORP Q3 FY2024 earnings call

Management Statement and Operational Highlights

• Strong third quarter financial results with 4.3% higher consolidated revenues to $240 million, record earnings from operations ($48 million, up 10% y/y), and record adjusted EBITDA ($64 million, up 7.6% y/y).
• Gross margin dollars grew 11.5%, and gross margin percentage expanded by 230 basis points to 35.6%.
• Market environment stabilization with customers returning to normalized order patterns.
• New product launches: AminoShure-XL (Animal Nutrition & Health), K2VITAL DELTA Fermented, and VitaCholine Pro-Flo (Human Nutrition & Health).

Segment Performance

• Human Nutrition & Health: Generated sales of $152 million, a 5.4% increase from the prior year. Delivered record quarterly earnings from operations of $36 million, up 13.8% compared to the prior year.
• Animal Nutrition & Health: Quarterly sales were $53 million, a 1.9% decrease from the prior year. Earnings from operations were $4 million, a 30.4% decrease from the prior year.
• Specialty Products: Quarterly sales of $33 million, a 10.6% increase from the prior year. Delivered quarterly earnings from operations of $11 million, a 20.3% increase versus the prior year.

Guidance

• Q4 is seasonally weakest, but expects continuation of growth in Human Nutrition & Health and Specialty Products segments.
• Anticipates sequential improvement in Animal Nutrition & Health segment in the second half of 2024.
• Margin rate expected to contract slightly in Q4 due to moderation in portfolio mix (lower margin Animal Nutrition & Health segment returning to growth) and plateauing input costs.

Risks

• Challenges in Animal Nutrition & Health segment due to soft market demand and competition from low-cost imports in Europe.
• Potential impact of changing interest rates and debt markets on capital allocation and M&A strategy.

Question and Answer

Q: Can you tell us more about your product development process? Where do you get your ideas from? How long is the time to develop and launch? And what is the pipeline for new stuff right now?

A: Ideas come from customers and marketing efforts. It typically takes about a year to bring an idea to fruition, sometimes a couple of years. External help is used to speed up development.

Q: What is the outlook for the minerals and nutrition subsegment in HNH over the next 12 months?

A: Minerals and nutrients business will continue to grow, though at a muted level due to comps. Food business growth expected to accelerate as market recovers.

Q: How have dairy farmers reacted in terms of demand for your product as milk prices rebound?

A: Dairy farmers are seeing improved net margins, leading to increased demand for feed additives and rumen-protected encapsulates. Order books are showing improvement but with a time lag for sustainability confirmation.

Q: How has Optifolin+ been doing so far?

A: Optifolin+ has annualized sales rate of about $2 million, ahead of expectations, with plans to showcase at SupplySide West conference.

Q: How do you anticipate allocating capital in terms of commercial support for HNH assets?

A: Will continue to allocate more capital to marketing and R&D for HNH. Increasing spend on social media marketing. Anti-aging is a focus area, with ancillary role in weight loss.

Q: What's your sense of the M&A market deal flow and potential uses of cash to return to shareholders?

A: M&A deal flow is improving. Capital allocation philosophy focuses on organic growth, M&A, debt repayment, dividend, and stock buybacks as last lever.

Q: Guidance for 4Q?

A: Margin rate expected to contract slightly due to portfolio mix moderation and input costs plateauing, but remains strong.